文章摘要

前列地尔在糖尿病肾病中的研究进展

作者: 1石 冰青, 1孙 广东
1 吉林大学第二医院肾内科,长春 130000
通讯: 孙 广东 Email: 13194317360@163.com
DOI: 10.3978/j.issn.2095-6959.2017.12.033

摘要

前列地尔注射液的主要成分前列腺素E1(prostaglandin E1,PGE1)是一种极强的生理活性物质,具有广泛的生理药理作用,可通过抑制血小板聚集、抑制炎症反应、扩张肾血管等多种途径治疗糖尿病肾病(diabetic nephropathy,DN),疗效佳、安全性良好。目前研究证实前列地尔注射液单独应用、序贯治疗或联合其它药物均可降低DN患者24 h尿蛋白定量、血肌酐、尿微量白蛋白及血尿素氮等相关指标,有效改善肾功能,延缓肾脏疾病进展且早期应用疗效更佳。另外,PGE1在DN的治疗中不良反应少,对于老年患者(60岁以上)仍具有较好的安全性,具有很高的临床应用价值。
关键词: 前列地尔注射液;糖尿病肾病;尿蛋白

Research progress of alprostadil in diabetic nephropathy

Authors: 1SHI Bingqing, 1SUN Guangdong
1 Department of Nephrology, Second Hospital of Jilin University, Changchun 130000, China

CorrespondingAuthor:SUN Guangdong Email: 13194317360@163.com

Abstract

Prostaglandin E1 (PGE1), a major component of prostaglandin injection, is a potent physiologically active substance with a wide range of physiological and pharmacological effects. It can be used to treat diabetic nephropathy (DN) through various mechnisims, such as inhibiting platelet aggregation, inhibiting inflammatory reaction and dilating renal vessels. It is effective and safe. The current study evidenced that alprostadil injection can be used alone, in sequential treatment or with other drugs. Any of these can reduce 24 h urinary proteinuria, serum creatinine, urinary albumin, blood urea nitrogen and other related indicators of DN, thus effectively improve renal function, and delay the progression of kidney disease, and it is more effective with early treatment. In addition,in the treatment of DN, PGE1 have less adverse effect. Even for elderly patients (60 years of age), it is still safe with high clinical value.
Keywords: alprostadil injection; diabetic nephropathy; urinary protein

Refbacks

  • There are currently no refbacks.